Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy
May 20 2014 - 9:00AM
Marketwired
Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box
Technology's Diverse Treatments Amid Biotech Frenzy
NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) is up to much more than most are currently aware of,
and it only takes a bit of digging to realize it. The company is
clearly out to extend the survival time of patients with advanced
inoperable pancreatic cancer in its upcoming Phase 2b clinical
trial, but reading the recently changed language in Nuvilex's
"About Nuvilex" section of its press releases, and it's also clear
they're not stopping there. It is the company's diversity with not
only pancreatic cancer, but with other cancers and diabetes, that
has it positioned for what could potentially be a lucrative deal
with a much larger pharmaceutical firm.
The new language in Nuvilex's press releases reads: Nuvilex is
also working towards clinical trials associated with the symptoms
of advanced pancreatic cancer and other abdominal cancers.
Abdominal cancer is defined as a type of cancer that occurs when
there is an uncontrolled growth of abnormal cells anywhere in the
abdomen, the area between the lower chest and the groin. The
abdomen consists of many organs, including the stomach, intestines,
liver, gallbladder, pancreas, esophagus, and numerous blood
vessels. Has Nuvilex stumbled onto something that the company's
Cell-in-a-Box® technology could provide a treatment for in all
stomach cancers and not just pancreatic cancer?
Well, another company, OncoMed Pharmaceuticals is currently
developing a number of therapies that target cancer stem cell
proteins to block their ability to replicate and proliferate
progenitor cells. This diverse approach has landed OncoMed several
big name biopharmaceutical partners including, GlaxoSmithKline,
Bayer, and what may be its biggest partner, Celgene Corp.
Back in December, OncoMed inked a mammoth deal with Celgene. In
that deal, Celgene put up $155 Million in upfront payments to
OncoMed, purchased $22.5 Million in OncoMed's common stock, and
pledged up to $3.3 Billion in milestone payments for the
co-marketing rights for up to six of OncoMed's therapies, including
demcizumab, and five preclinical therapies.
Demcizumab is a mid-stage product that completed a Phase 1
pancreatic cancer clinical trial combined with Gemzar
(gemcitabine), and the pancreatic cancer angle could be why Celgene
has not only shown interest but has invested in its future.
With a biotech frenzy, of sorts, underway in 2014, Nuvilex's
pancreatic cancer treatment using Cell-in-a-Box® combined with the
anticancer drug ifosfamide may very well prove that it too is a
diverse solution to fighting a number of cancers, and if so, having
the likes of Celgene as a competitor could also have Celgene ready
to get involved with its success much like it's doing with
OncoMed.
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex content by a third party who reserves the
right to buy, sell or remain neutral on securities after the
publication of this article. SMMG has received total compensation
of $87,580 for content related to Nuvilex. Additionally, a
principal at SMMG currently owns 200,000 total shares of Nuvilex
issued by the company through a consulting agreement which has
since ended for work unrelated to content development. The shares
have been held for the requisite period under Rule 144 as of April
30, 2013, and are eligible to be sold immediately without further
notice. For more information: www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact